Opinion: miRNAs – The new wave of molecular cancer therapeutics

Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Bertoni, Hernando, Laterra, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957095/
https://www.ncbi.nlm.nih.gov/pubmed/33721829
http://dx.doi.org/10.1016/j.tranon.2021.101064
_version_ 1783664584483143680
author Lopez-Bertoni, Hernando
Laterra, John
author_facet Lopez-Bertoni, Hernando
Laterra, John
author_sort Lopez-Bertoni, Hernando
collection PubMed
description Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.
format Online
Article
Text
id pubmed-7957095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-79570952021-03-24 Opinion: miRNAs – The new wave of molecular cancer therapeutics Lopez-Bertoni, Hernando Laterra, John Transl Oncol Perspective Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation. Neoplasia Press 2021-03-12 /pmc/articles/PMC7957095/ /pubmed/33721829 http://dx.doi.org/10.1016/j.tranon.2021.101064 Text en © 2021 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Lopez-Bertoni, Hernando
Laterra, John
Opinion: miRNAs – The new wave of molecular cancer therapeutics
title Opinion: miRNAs – The new wave of molecular cancer therapeutics
title_full Opinion: miRNAs – The new wave of molecular cancer therapeutics
title_fullStr Opinion: miRNAs – The new wave of molecular cancer therapeutics
title_full_unstemmed Opinion: miRNAs – The new wave of molecular cancer therapeutics
title_short Opinion: miRNAs – The new wave of molecular cancer therapeutics
title_sort opinion: mirnas – the new wave of molecular cancer therapeutics
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957095/
https://www.ncbi.nlm.nih.gov/pubmed/33721829
http://dx.doi.org/10.1016/j.tranon.2021.101064
work_keys_str_mv AT lopezbertonihernando opinionmirnasthenewwaveofmolecularcancertherapeutics
AT laterrajohn opinionmirnasthenewwaveofmolecularcancertherapeutics

Ejemplares similares